

## PRODUCT INFORMATION

<b>Common Name</b>	ACD22-VCMMAE, DCDT2980S, FCU2803, RG-7593, RO5541072-000, Unconjugated mAb
<b>Synonyms</b>	CD22;SIGLEC2;BL-CAM;SIGLEC-2;Siglec2;SIGLEC2FLJ22814
<b>Conjugate</b>	Unconjugated
<b>Applications</b>	ELISA; Flow Cyt
<b>Recommended Dilutions</b>	ELISA 1:5000-10000; Flow Cyt 1:100
<b>Formulation &amp; Reconstitution</b>	Lyophilized from sterile PBS, pH 7.4. Normally 5 % - 8% trehalose is added as protectants before lyophilization. Please see Certificate of Analysis for specific instructions of reconstitution.
<b>Host Species</b>	Humanized
<b>IgG type</b>	Human IgG1 - kappa
<b>Reactivity</b>	Human
<b>Target</b>	CD22
<b>Uniprot ID</b>	P20273
<b>Description</b>	Anti-CD22 (pinatuzumab biosimilar) mAb
<b>Delivery</b>	In Stock
<b>Storage&amp;Shipping</b>	Store at -20°C to -80°C for 12 months in lyophilized form. After reconstitution, if not intended for use within a month, aliquot and store at -80°C (Avoid repeated freezing and thawing). Lyophilized proteins are shipped at ambient temperature. Research grade biosimilar. Not for use in therapeutic or diagnostic procedures for humans or animals. Our unconjugated biosimilar monoclonal antibodies (mAbs) are based on the sequences outlined in relevant patents or scientific publications. These antibodies are in their native, unconjugated form, meaning they do not contain any payload or therapeutic agent attached. They are designed for use in research and development, and their performance has been tested as standalone molecules through comprehensive QC tests.
<b>Background</b>	Research use only



## Anti-CD22 (pinatuzumab vedotin biosimilar) mAb ELISA





Figure 1. ELISA plate pre-coated by 2 µg/ml (100 µL/well) Human CD22, hFc-His tagged protein (PME100005) can bind Anti-CD22 Neutralizing antibody in a linear range of 3.2-400 ng/ml. In order to specifically detect BME100029, mouse anti-human Fab-specific antibody was used as detection antibody.



**Figure 2.** HEK293 cell line transfected with irrelevant protein **(B)** and human CD22 **(A)** were surface stained with Anti-CD22 mAb 1 µg/ml (pinatuzumab) followed by Alexa 488-conjugated anti-human IgG secondary antibody.

